Polaryx Therapeutics is a late-stage clinical biotech combating Lysosomal Storage Disorders (LSDs). We are focused on developing patient-friendly small molecule and gene therapy treatments for lysosomal storage disorders, including neuronal ceroid lipofuscinosis, Krabbe disease, Sandhoff disease, and Niemann Pick Type A / B diseases.
Company Details
- Employees
- 7
- Founded
- -
- Address
- 140 E. Ridgewood Ave.,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- polaryx.com
- Keywords
- Lysosomal Storage Disorders, Neuronal Ceroid Lipofuscinosis, Batten disease, Krabbe disease, Niemann Pick disease, Tay Sachs disease.
- HQ
- Paramus, NJ
Polaryx Therapeutics Questions
Polaryx Therapeutics's website is polaryx.com
Polaryx Therapeutics's LinkedIn profile is https://www.linkedin.com/company/polaryxtherapeutics
Polaryx Therapeutics has
7 employees.
View email and phone details for 7
employees at Polaryx Therapeutics.
Polaryx Therapeutics's industry is
Biotechnology Research
Polaryx Therapeutics's top competitors are
Incsd,
Liberyx Therapeutics,
Mstone Partners,
Tolero Pharmaceuticals, Inc.,
Sling Ventures,
7 Primus Biosciences, Inc.,
Bioanalytica Inc.,
Forest Hills Lab,
Actimis Pharmaceuticals,
Affymax Research Institute.
Polaryx Therapeutics's categories are Biotechnology Research
Polaryx Therapeutics's founding year is 2014
